Skip directly to site content Skip directly to search


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB Genotyping Information Management System (TB GIMS)										Related Pages
										**TB Genotyping Information Management System (TB GIMS)**
**What is TB GIMS?**
The TB Genotyping Information Management System (TB GIMS) is a secure web-based system that:
Stores and manages genotyping data on TB patients in the United States
Allows users to submit and track *Mycobacterium tuberculosis* isolates to and from the contract genotyping labs
Provides immediate notification of genotyping results and updates to TB labs and programs
Links isolate data to patient-level surveillance data
Provides reports on genotype clusters, including national genotype distribution
Provides national, state, and county maps of genotype clusters**What are the objectives of TB GIMS?**
To improve access to and dissemination of genotyping information nationwide
To serve as a standard database that local programs can use to
Track *Mycobacterium tuberculosis* complex isolates sent to contract genotyping laboratories
Receive and update genotyping information on TB patients
Access nationwide genotyping information
To provide a way to alert users about potential TB outbreaks in their jurisdictions**Who are the primary users of TB GIMS?**
TB laboratories that submit isolates for genotyping
Contract genotyping laboratories in California and Michigan
TB programs
CDC**How do I access TB GIMS?**
Access to TB GIMS shall be coordinated by a designated person in a state known as TB GIMS Administrator. Check with the TB Controller in your state for details. Registration for TB GIMS will be done in phases, starting in spring 2010. There are different user roles and access levels in TB GIMS:
Super User
Standard User(See table 1 for more information on user roles)
**What can a Super User do?**
Super Users will have unrestricted access to TB GIMS for their approved jurisdiction. They will be able to update, edit, enter, upload, review, search, import, and export all TB GIMS data.
CDC suggests that most jurisdictions should designate two Super Users. It is suggested that the two Super Users be the:
Person in the laboratory with primary responsibility for submitting isolates to the genotyping laboratories; and
Person from the TB program with the primary responsibility for managing, validating, and analyzing genotype-related activities for their jurisdictions.**What can a Standard User do?**
A Standard User has access to genotyping data, but cannot edit data in the system. Standard Users can search for genotyping results by case (using patient identifiers) or by specific genotype strains (e.g., spoligotype or MIRU patterns), and can view details related to their queries on genotype clusters.
CDC assumes that most TB GIMS users will be Standard Users. TB Program managers and other staff who use genotype data in contact investigations, TB program evaluation, incident response, and other TB control activities are suggested to be Standard Users.
**What can a Restricted-Access User do?**
Restricted-Access Users will not have access to patient identifiers, but will be able to view aggregate summary data reports. CDC envisions Restricted-Access Users to be partners not directly involved with patient-level or programmatic activities.
**Table 1: TB GIMS User Roles**

Table 1: TB GIMS User Roles
Super User
Standard UserAccess to GIMS data?
Unrestricted access
Regular accessSearch Data?
Yes
YesView Data?
Can view aggregated data
Can see line-listed dataWill have access to patient identifiers
Can view aggregated data
Can see line-listed data
Will have access to patient identifiersEdit Data?Export Data?
Yes
Can export line-listed data
Can export reports
Yes
Can export line-listed data
Can export reportsView Maps?
Can view national, state, and county level maps at zip code level
Can view national, state, and county level maps at zip code levelTypical Users?
Program epidemiologists, genotype coordinators, who deal with genotype-related activities on a daily basis
Program managers and other staff who use genotype data in contact investigations, TB program evaluation, incident response, and other TB control activities**Is there a difference between an Administrator and a Super User?**
An Administrator may or may not be a Super User. If an Administrator chooses to be a Super User, he or she is responsible for regular maintenance of the TB GIMS data along with providing a list of applicants for their jurisdiction.
**How does TB GIMS affect laboratories that submit isolates for genotyping?**
TB GIMS will replace the Excel spreadsheets that were previously used to submit isolates and receive genotyping results. Laboratories that routinely submit isolates to the contract genotyping laboratory should register for user access for their jurisdiction. Laboratory user roles will be similar to TB program user roles (e.g., Super User, Standard User) and will have laboratory-specific functions such as submitting and tracking isolates to and from the contract genotyping laboratories.
**Will Regional Training and Medical Consultation Centers (RTMCCs) and other academic institutions be able to access TB GIMS?**
Users who want TB GIMS data from multiple jurisdictions will need to apply for access to each of the desired jurisdictions. For example, if the Heartland National TB Center wants to view genotyping data for the states in their region, the nurse consultant from the Center would apply to each state in their region for access as a user. This feature will not be available in the first phase that will be released in 2010.
**Will TB GIMS allow for sharing genotyping data across jurisdictions?**
TB GIMS does allow for sharing data across jurisdictions. All users will have access to maps and aggregate cluster distribution reports similar to currently disseminated reports “National Distribution Reports.” Patient-level data cannot be shared across jurisdiction in the first phase that will be released in 2010.
**How is information protected in TB GIMS?**
CDC is committed to maintaining strict confidentiality and security of the national surveillance information through the National TB Surveillance System (NTSS). TB GIMS is an extension of NTSS and will be protected in the following ways:
Data encryption will be employed when data is transmitted between users and TB GIMS;
Multi-factor authentication will be used upon logon to prevent unauthorized users from gaining access to the system;
TB GIMS will be housed on servers that are protected by reverse proxy firewalls to prevent unauthorized access to the system;
TB GIMS is designed to display data/information based on user roles to ensure users only have access to what they have been authorized by Administrators;
All potential users must be authorized by local TB GIMS Administrators.**What are CDC data use agreements and “rules of behavior”?**
CDC data use agreements and “rules of behavior” provide general instructions on the appropriate use of Information Technology resources. “Rules of behavior” are not to be used in place of existing policy. Rather they are intended to supplement the Health and Human Services (HHS) Information Security Program Policy. All TB GIMS users must sign these agreements electronically to access and view genotype data.
**What will happen to previously submitted genotyping data?**
When TB GIMS is rolled out, CDC will populate the online database with all of the previously submitted data to date. This linked data will be available to generate the standard reports and query for already existing clusters.
**Can data be exported from TB GIMS? In what format**?
Data can be exported from TB GIMS by Super Users only. The current format for exporting line-listed data is in an Excel spreadsheet, which can be manipulated directly or imported into a statistical package of your choice.
For all other queries and standard reports and maps, PDF format will be used and data can be printed directly from TB GIMS by using a simple print function at the bottom of each screen.
**How much will TB GIMS cost users and public health departments?**
TB GIMS is a web-based application provided by CDC for better dissemination and understanding of genotyping results and reports. It is available to users and health departments free of charge.
**Additional Information**
For more information on TB GIMS, please contact DTBESupport@cdc.gov.
							
					
						Page last reviewed:  September 1, 2012					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue